NEWS

September 23, 2022
Travere Wins PM360 Trailblazer Specialty Pharma/Biotech Company of the Year Award for its Work in Rare Disease
September 14, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 6, 2022
Jula Inrig Named to PharmaVoice 100 Top Industry Leaders List for 2022
August 25, 2022
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
August 22, 2022
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
August 17, 2022
Travere Therapeutics Named Finalist for the 2022 PM360 Magazine Trailblazer Specialty Pharma/Biotech Company of the Year Award
August 11, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 9, 2022
Travere Therapeutics Named 2022 Bronze Winner of The Stevie Awards for Great Employers
August 4, 2022
Travere Therapeutics Reports Second Quarter 2022 Financial Results
August 3, 2022
Travere Therapeutics Provides Regulatory Updates on its Development Programs
July 28, 2022
Travere Therapeutics to Report Second Quarter 2022 Financial Results
July 12, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)